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Study Highlights  1 
 2 
WHAT IS KNOWN 3 
 Nonalcoholic fatty liver disease (NAFLD) is associated with the risk of cardio-4 
metabolic disease.  5 
 Inadequate sleep duration is related to obesity, metabolic syndrome, and cardiovascular 6 
disease. 7 
 The cohort studies on the relationship of sleep duration and NAFLD show conflicting 8 
results. 9 
 10 
WHAT IS NEW HERE 11 
 Short sleep duration is a risk factor for developing NAFLD with or without fibrosis. 12 
 BMI only partially mediated the association between sleep duration and NAFLD. 13 





Objectives: The longitudinal relationship between sleep duration, sleep quality, and the risk of 2 
non-alcoholic fatty liver disease (NAFLD) is unknown. We aimed to examine the association 3 
between sleep duration, sleep quality, and NAFLD development. 4 
Methods: 143,306 NAFLD-free Korean adults with a mean age of 36.6 years were followed 5 
for an average of 4.0 years. Sleep duration and quality were assessed using the Pittsburgh Sleep 6 
Quality Index. Hepatic steatosis (HS) was assessed using ultrasonography and liver fibrosis by 7 
the fibrosis-4 index (FIB-4) or the NAFLD fibrosis score (NFS). Flexible parametric 8 
proportional hazard models were used to determine the hazard ratios (HRs) and 95% confidence 9 
intervals (CIs). 10 
Results: 21,817 subjects with incident HS were identified of whom 1471 had incident HS plus 11 
intermediate/high FIB-4. Multivariable-adjusted HR (95% CIs) for incident HS comparing 12 
sleep durations of ≤5, 6, 8, and ≥ 9 hours with 7 hours were 1.19 (1.14-1.23), 1.07 (1.04-13 
1.10), 0.98 (0.94-1.02), and 0.95 (0.87-1.03), respectively. The corresponding HRs for incident 14 
HS plus intermediate/high FIB-4 were 1.30 (1.11-1.54), 1.14 (1.01-1.29), 1.11 (0.93-1.33) and 15 
1.08 (0.71-1.63). The association between sleep duration and HS plus intermediate/high FIB-4 16 
was inverse in individuals with good sleep quality but tended to be U-shaped in those with poor 17 
sleep quality. The results were similar if FIB-4 was replaced by the NFS. 18 
Conclusions: In young adults, short sleep duration was independently associated with an 19 
increased risk of incident NAFLD with or without intermediate/high fibrosis score, suggesting 20 
a role for inadequate sleep quantity in NAFLD risk and severity. 21 
Keywords: Hepatic steatosis; Hepatic fibrosis; Sleep quality; Pittsburg sleep quality index; 22 




Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver disorders 1 
worldwide,(1) with a global prevalence of approximately 25%.(2) NAFLD is now considered 2 
a multisystem disease that is associated with cardiometabolic disorders, all-cause mortality and 3 
cardiovascular disease (CVD) mortality.(3, 4) There are currently no approved medical 4 
therapies,(5) and the first-line treatment for NAFLD management is lifestyle modification.(6) 5 
Thus, it is important to identify all modifiable lifestyle factors, as it is plausible that 6 
improvements in each of these factors may help prevent the development of NAFLD. 7 
We spend, on average, a one-third of our lifetime sleeping. Sleep has been reported to play a 8 
pivotal role in cardiovascular health, as well as the endocrine and immune systems.(7, 8) 9 
However, in recent decades, sleep duration has decreased, with a reported prevalence of short 10 
sleep duration (defined as <6 h) reaching over 20%.(9) A decrease in sleep duration may 11 
adversely affect insulin sensitivity and inflammatory activity,(8, 10) and may therefore 12 
contribute to the development of NAFLD. Epidemiological studies have also suggested that 13 
short sleep duration is closely associated with obesity, metabolic syndrome, and CVD,(11, 12) 14 
all of which are also commonly observed in patients with NAFLD.(13) Currently, the 15 
relationship between sleep duration and NAFLD is controversial. A meta-analysis reported a 16 
small but significant association between short sleep duration and increased risk of NAFLD,(14) 17 
whereas another meta-analysis showed no significant association between sleep duration and 18 
the risk of fatty liver disease.(15) However, the findings from both these meta-analyses were 19 
determined mostly based on results from cross-sectional studies. Currently, available cohort 20 
studies on this association have limitations, including small sample sizes, lack of consideration 21 
of sleep quality and changing status of sleep habits over time, and the inclusion of elderly adults 22 
who already had a high number of comorbidities, including sleep problems.(16-19) 23 
Furthermore, none of the cohort studies evaluated the impact of sleep duration on the 24 
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development of the more severe form of NAFLD, incident NAFLD with liver fibrosis, the most 1 
important predictor of liver and non-liver mortality.(20, 21) 2 
This study aimed to evaluate the relationship between sleep duration and sleep quality and 3 
the development of incident hepatic steatosis (HS) with and without an intermediate/high 4 
probability of liver fibrosis while accounting for time-dependent measures of change in sleep 5 
duration, sleep quality, and potential confounders during the follow-up period. 6 
 7 
MATERIALS AND METHODS 8 
Study population 9 
This cohort study is a part of the Kangbuk Samsung Health Study, a cohort study of Korean 10 
adults who participated in a health examination annually or biennially at Kangbuk Samsung 11 
Hospital Total Healthcare Centers in Seoul and Suwon, South Korea as previously 12 
described.(22) The present study population was restricted to individuals who underwent a 13 
health screening examination with information on sleep duration and sleep quality from 14 
March 2011 to December 2017 and had at least one follow-up visit by December 31, 2019 (N 15 
= 295,404). A total of 143,964 subjects met one or more of the exclusion criteria at baseline 16 
(Figure 1). The final sample included 143,306 subjects in the analysis. This study was 17 
approved by the Institutional Review Board of Kangbuk Samsung Hospital (IRB 2021-01-18 
024) and was conducted in accordance with the Declaration of Helsinki. The requirement for 19 
informed consent was waived due to the use of a preexisting de-identified dataset that was 20 
routinely collected during the health screening process. 21 
 22 
Data collection 23 
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Data regarding the patient’s demographic characteristics, behavioral factors, and medical 1 
history were collected using a standardized, self-administered questionnaire, while 2 
anthropometry, blood pressure, and serum biochemical parameters were measured by trained 3 
staff during the health examinations. 4 
Sleep duration and quality were assessed using the validated Pittsburgh Sleep Quality Index 5 
(PSQI), 19-item self-administered questionnaire, at baseline and during the follow-up sessions 6 
(23) (further details in Supporting Documents).  7 
The diagnosis of HS was based on an abdominal ultrasound performed by an experienced 8 
radiologist who was blinded to the aim of the present study. To assess severity of NAFLD, 9 
two non-invasive indices of liver fibrosis were used: the fibrosis-4 index (FIB-4) and NAFLD 10 
fibrosis score (NFS) (24, 25) (further details in Supporting Documents).  11 
 12 
Statistical analysis 13 
The primary endpoints were a) the development of incident HS (regardless of fibrosis score) 14 
and b) the development of incident HS plus an intermediate/high probability of liver fibrosis. 15 
Incident HS, and incident HS combined with an intermediate/high probability of liver fibrosis 16 
based on the FIB-4 or NFS, were treated as separate endpoints in each model. The event 17 
detection date was defined as the earliest date of identification of HS or HS with an 18 
intermediate/high probability of liver fibrosis based on the FIB-4 score or NFS, which were 19 
analyzed separately. The person-years were calculated as the sum of the follow-up duration 20 
from baseline to the event detection date (HS or HS with fibrosis, separately) or until the final 21 
examination (before December 31, 2019), whichever occurred first. Incidence rates were 22 
calculated as the number of incident cases divided by the person-years of follow-up. 23 
Therefore, as the primary endpoint occurred at an unknown time point between the event 24 
9 
 
detection date and the previous screening visit, a parametric proportional hazards model was 1 
used to account for this type of interval censoring and to estimate the hazard ratios (HRs) and 2 
95% confidence intervals (CIs). In these models, the baseline hazard function was 3 
parameterized with restricted cubic splines in log time with four degrees of freedom. We 4 
assessed the proportional hazards assumption by examining graphs of estimated log 5 
(−log(survival)) versus the log of survival time graph. No violation of the assumption was 6 
found. 7 
The risk of incident HS and incident HS combined with an intermediate/high probability of 8 
liver fibrosis were separately evaluated according to the sleep duration category (further 9 
details in Supporting Documents).  10 
Statistical analyses were performed using STATA version 16.0 (StataCorp LP, College 11 
Station, TX, USA). All reported P-values were two-tailed, and a P-value of < 0.05 was 12 
considered statistically significant. 13 
 14 
RESULTS 15 
 At baseline, the mean (SD) age and sleep duration of 143,306 subjects were 36.6 (6.6) years 16 
and 7.0 (1.1) h, respectively. The prevalence of poor sleep quality was 20.1% and was 17 
inversely associated with sleep duration, with the highest prevalence seen in those with a 18 
short sleep duration of ≤5 h (45.8%). The sleep duration categories were positively 19 
associated with being married but were inversely associated with age, male sex, current 20 
smoking, alcohol drinking, depressive symptoms, and obesity as described in Table 1. 21 
During 618,582.6 person-years of follow-up, 27,817 cases of incident HS were 22 
identified (incidence rate 45.0 per 103 person-years). Median follow-up was 4.0 years 23 
(interquartile range, 2.1-6.1). After adjustment for age, sex, the center, year of the screening 24 
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exam, season, alcohol consumption, smoking, physical activity, total energy intake, marital 1 
status, education level, depressive symptoms, history of diabetes, and history of hypertension 2 
(Table 2), multivariable-adjusted HR (95% CIs) for incident HS comparing sleep durations of 3 
≤5, 6, 8, and ≥ 9 h with 7 h were 1.19 (1.14-1.23), 1.07 (1.04-1.10), 0.98 (0.94-1.02), and 0.95 4 
(0.87-1.03), respectively. After further adjustment for BMI (Model 3), the association between 5 
short sleep duration and incident HS was attenuated but remained statistically significant. 6 
Results were similar if BMI was replaced by the waist circumference (Model 4). In time-7 
dependent analyses where change in sleep duration, sleep quality and other covariates during 8 
follow-up were treated as a time-varying covariate, these results were similar. In the spline 9 
regression analyses, there was a dose-response relationship between sleep duration and the 10 
development of NAFLD (Figure 2). 11 
During 680,986.1 person-years of follow-up, 1,471 cases of incident HS plus an 12 
intermediate/high FIB-4 were identified (incidence rate 2.2 per 103 person-years). After 13 
adjustment for potential confounders, the multivariable-adjusted HR (95% CI) for incident HS 14 
plus an intermediate/high FIB-4, comparing sleep durations of ≤5, 6, 8, and ≥ 9 h with 7 h 15 
(reference) were 1.30 (1.11-1.54), 1.14 (1.01-1.29), 1.11 (0.93-1.33), and 1.08 (0.71-1.63), 16 
respectively. Results were similar based on the NFS. After further adjustment for BMI (Model 17 
3), the association between short sleep duration and incident HS plus intermediate/high fibrosis 18 
markers remained significant. In contrast, poor sleep quality was not significantly associated 19 
with the risk of either incident HS or HS plus intermediate/high fibrosis markers (Tables 2 and 20 
3). All these associations were consistently observed in both males and females without 21 
significant interaction by sex.  22 
The associations between sleep duration and risk of HS were similarly observed in 23 
those with or without poor sleep quality (P for interaction= 0.734), whereas the association 24 
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between sleep duration and HS plus intermediate/high fibrosis markers significantly differed 1 
by sleep quality (Table 4). There was an inverse association between sleep duration and HS 2 
plus an intermediate/high FIB-4 in individuals with good sleep quality but it tended to be U-3 
shaped in those with poor sleep quality. These associations were similarly observed in the 4 
analysis using NFS instead of FIB-4. 5 
Since obesity is closely associated with HS and sleep duration is also related to 6 
obesity, we performed analyses among non-obese individuals to address residual confounding 7 
factors due to obesity. The associations between sleep duration, HS, and HS plus an 8 
intermediate/high FIB-4 were similar in non-obese individuals with a BMI of <25 kg/m2. 9 
Specifically, after adjustment for age, sex, center, year of screening exam, alcohol 10 
consumption, smoking, physical activity, season, total energy intake, marital status, education 11 
level, depression and history of hypertension, multivariable-adjusted HR (95% CIs) for 12 
incident HS regardless of fibrosis score comparing sleep durations of ≤5, 6, 8, and ≥ 9 h with 13 
7 h were 1.17 (1.12-1.22), 1.07 (1.04-1.11), 0.98 (0.93-1.02), and 0.88 (0.80-0.97), 14 
respectively. The corresponding HRs (95% CIs) for HS plus an intermediate/high FIB-4 were 15 
1.38 (1.05-1.79), 1.20 (0.98-1.47), 1.13 (0.86-1.49), and 1.20 (0.68-2.11), respectively.  16 
 17 
DISCUSSION 18 
 In this large-scale prospective cohort study of relatively young adults with a median age 19 
of 36.6 years, a median follow-up of over four years and the availability of repeated 20 
measurements of sleep habits, NAFLD status, and other covariates, short sleep duration was 21 
found to be independently associated with an increased risk of developing NAFLD both with 22 
and without an intermediate/high fibrosis score. These associations between short sleep 23 
duration and increased risk of developing NAFLD were attenuated after adjustment for either 24 
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BMI or waist circumference, but still remained significant. Additionally, the associations 1 
remained significant after adjustment for changes in sleep duration and other confounders 2 
over time, (as time-varying covariates in the time-dependent models). Interestingly, sleep 3 
quality was not significantly associated with the risk of NAFLD and the association between 4 
sleep duration and HS did not significantly differ by sleep quality. However, the association 5 
between sleep duration and HS plus intermediate/high FIB-4 significantly differed by sleep 6 
quality. In individuals with good sleep quality, sleep duration was inversely associated with 7 
HS plus an intermediate/high FIB-4 in a dose-response manner, while both short and long 8 
sleep durations were associated with an increased risk of HS plus an intermediate/high FIB-4, 9 
showing a U-shaped association in those with poor sleep quality. The reason for the increased 10 
risk of HS plus an intermediate/high FIB-4 level among individuals with long sleep duration 11 
in those with poor sleep quality, and the decreased risk in those with good sleep quality, is not 12 
fully understood. Compared with individuals with normal sleep duration, those with long 13 
sleep duration have been reported as having a higher risk of obstructive sleep apnea and 14 
insomnia symptoms, such as increased sleep fragmentation, wake after sleep onset, and sleep 15 
latency(26). Additionally, habitually long sleep duration has been reported to be associated 16 
with poor physical and mental health status(27, 28); thus, excessively long sleep duration may 17 
be an indicator of coping with and compensating for this poor sleep quality and other 18 
unmeasured features of poor health status(26-28). 19 
A meta-analysis including five cross-sectional studies and one cohort study found a small 20 
but significantly increased risk of NAFLD among individuals with a short sleep duration 21 
compared to those with a longer sleep duration.(14) In contrast, another meta-analysis of six 22 
cross-sectional studies and two cohort studies found that neither short nor long sleep duration 23 
was related to NAFLD risk.(15) However, these meta-analyses were both limited in that they 24 
13 
 
included only a few cohort studies; the former only included one cohort study,(14) and the 1 
latter two cohort studies.(15) 2 
An earlier cohort study of 2133 middle-aged Japanese patients showed an association between 3 
short sleep duration and reduced risk of NAFLD (17), whereas a recent cohort study of 4 
12,306 Japanese adults reported a significant association between short sleep duration and 5 
increased risk of NAFLD (19). A cohort study of 5427 Korean adults reported that long sleep 6 
duration was associated with an increased incidence of NAFLD, based on the NAFLD scores 7 
rather than on ultrasonography.(29) Finally, a different cohort study of 8965 Chinese subjects 8 
with a mean age of 61.6 years demonstrated a positive association between long sleep 9 
duration (8-9 h/day) and new-onset NAFLD. (16) However, this study was limited in that it 10 
only included a very small number of subjects in the short sleep duration category (only 96 11 
subjects with a sleep duration of <6 h).(16) Also, the prevalence of sleep disorders increases 12 
with age, and approximately 50% of the elderly have sleep problems.(30) None of previous 13 
studies evaluated the impact of sleep quality as either the main exposure or effect modifier on 14 
the risk of incident NAFLD. 15 
 Several plausible mechanisms may explain the association between sleep and NAFLD. Sleep 16 
deprivation may increase the ghrelin but decrease leptin levels, causing a rise in appetite,(31) 17 
subsequently resulting in weight gain and obesity, which is a strong risk factor for 18 
NAFLD.(1) In our study, adjustment for either BMI or waist circumference attenuated the 19 
relationship between sleep duration and incident HS or HS plus an intermediate/high FIB-4, 20 
but the results remained statistically significant. Furthermore, this association was observed in 21 
non-obese individuals with a BMI < 25 kg/ m2. Therefore, the association between sleep 22 
duration and NAFLD appears to not be fully explained by obesity. However, given that the 23 
association between sleep duration and NAFLD risk was attenuated by approximately 14% 24 
14 
 
after adjustment for BMI or waist circumference, the role of overall and abdominal obesity is 1 
likely to contribute to the association between sleep duration and NAFLD risk. Studies 2 
suggest that sleep deprivation and sleep disturbance can decrease insulin sensitivity,(10, 32) a 3 
key pathogenic mechanism of NAFLD. Second, sleep deprivation provokes proinflammatory 4 
activity (e.g., increased IL-6 or TNF-alpha(32, 33)),39 41 which can induce inflammation, 5 
another mechanism of NAFLD. Furthermore, melatonin is known to function as a strong 6 
antioxidant, and low levels of melatonin may influence liver disease.(34) In support of the 7 
beneficial effect of melatonin, a randomized controlled trial of 100 patients with 8 
histologically proven NAFLD showed a beneficial effect of melatonin treatment on liver 9 
enzyme levels.(35) 10 
 A major strength of our study is that we have shown the effect of sleep duration and sleep 11 
quality on NAFLD and its severity using a large-scale cohort. Additionally, the availability of 12 
repeated measurements of sleep habits, NAFLD status, and other covariates enabled us to take 13 
into account the effects of changes in these variables as time-varying covariates. Furthermore, 14 
our findings are derived from a relatively young population less likely to be affected by 15 
survivor bias or bias related to comorbidities. However, age is an important risk factor for 16 
NAFLD and its progression (36, 37). Therefore, our findings derived from young adults may 17 
not be generalizable to older populations. However, recent studies suggest that the prevalence 18 
of hepatic steatosis and fibrosis is increasing in younger populations(38, 39). The results of 19 
our study emphasize the importance of starting lifestyle modifications at an early age to 20 
prevent progression of the disease. Currently, the risk factors for lean NAFLD are not fully 21 
understood,(40) despite an increase in its prevalence, especially in Asians.(41) Importantly, 22 
our study findings suggest that short sleep duration could be a risk factor for lean NAFLD, as 23 
we also know that short sleep duration is associated with an increased risk of NAFLD in non-24 
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obese subjects. The effect size was comparably small. However, we emphasize that NAFLD 1 
is one of the most common liver diseases worldwide and sleep shortage is common, with an 2 
estimated prevalence of over 20% (9, 42). In the absence of approved medication for NAFLD, 3 
healthy lifestyle adoption, which also includes better quality and adequate sleep duration, 4 
continues to be at the center of primary and secondary prevention of this disease.  5 
There were several limitations to our study. First, sleep duration was self-reported in the PSQI 6 
questionnaire, which has been reported to show a moderate correlation with objectively 7 
measured sleep duration(43). In a study of 112 volunteers, consisting of a group aged 18–32 8 
years (n=59) and an older group aged 59–75 years (n=53), the global and component scores of 9 
the PSQI correlated well with sleep diary variables and CES-D scores(44). In contrast, the 10 
PSQI score did not correlate with sleep variables measured using Actigraph accelerometers in 11 
the whole group, while significant correlations were only observed between the PSQI sleep 12 
duration component and total sleep time in the younger group(44). Further studies with 13 
objective and subjective sleep measures are required to confirm the relationship between sleep 14 
quantity and quality and NAFLD risk. Second, a histologic assessment of the liver was not 15 
performed. However, abdominal ultrasonography is widely used in large cohort studies, as a 16 
measure to diagnose hepatic steatosis with acceptable diagnostic accuracy for the detection of 17 
fatty liver.(45) Although a high FIB-4 or NFS is a validated proxy measure of high 18 
probability of advanced liver fibrosis(24), it is possible that some subjects with intermediate 19 
FIB-4 or NFS scores do not have liver fibrosis. Finally, our study population comprised 20 
relatively young and middle-aged Koreans, possibly limiting the generalizability of our 21 
findings to other age groups, populations with a higher prevalence of comorbidities, or other 22 
ethnic groups.  23 
In conclusion, our results show that short sleep duration was associated with an increased risk 24 
16 
 
of incident NAFLD, both with and without intermediate/high fibrosis scores at follow up. We 1 
suggest that interventional studies that modify sleep duration are necessary to test whether 2 
there is a beneficial effect of ameliorating sleep deprivation on the risk of NAFLD. 3 
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Table 1. Baseline characteristics of participants by sleep duration 
Characteristics 
Overall 
Sleep duration (hours) 
≤ 5 6 7 8 ≥ 9 
Number 143,306 19,003 48,163 49,589 21,766 4,785 
Age (years)a 36.6 (6.6) 36.7 (7.0) 36.8 (6.8) 36.6 (6.5) 36.2 (6.3) 35.2 (6.1) 
Men (%) 38.5 40.2 47.4 39.0 22.4 8.6 
Obesity (%) 11.8 14.1 13.6 11.0 8.6 7.1 
Current smoker (%) 13.3 15.8 15.8 12.9 8.0 3.8 
Alcohol intake (%)b 25.0 27.4 29.2 24.6 17.1 12.4 
Alcohol intake, gram/day 6.2 (6.5) 6.6 (6.8) 6.9 (6.9) 6.1 (6.5) 4.8 (5.5) 3.8 (4.6) 
 Men  9.9 (7.7) 10.2 (7.9) 10.1 (7.7) 9.8 (7.7) 9.4 (7.6) 9.2 (7.4) 
 Women  3.7 (3.9) 3.9 (4.2) 3.9 (4.0) 3.6 (3.9) 3.4 (3.7) 3.3 (3.8) 
HEPA (%) 14.1 15.5 14.3 14.1 13.1 11.5 
High education (%)d 87.9 86.8 88.9 88.6 86.0 82.7 
Married (%) 78.4 72.1 74.9 79.8 86.0 90.7 
Depression (%) 11.6 19.7 11.8 9.2 9.5 11.9 
Hypertension (%) 4.4 4.9 4.9 4.3 3.2 2.3 
Diabetes (%) 0.7 0.8 0.8 0.7 0.6 0.6 
History of CVD (%) 0.8 1.0 0.9 0.7 0.4 0.8 
BMI (kg/m2) 21.9 (2.6) 22.1 (2.7) 22.1 (2.6) 21.8 (2.6) 21.4 (2.6) 21.0 (2.5) 
Waist circumference (cm) 77.0 (7.2) 77.5 (8.1) 77.8 (8.1) 76.8 (7.9) 75.5 (7.6) 74.3 (7.2) 
Systolic BP (mmHg)a 104.8 (11.7) 104.9 (11.7) 105.8 (11.8) 104.9 (11.8) 103.0 (11.3) 101.1 (10.5) 
Diastolic BP (mmHg)a 66.9 (8.8) 66.9 (8.8) 67.5 (8.9) 67.0 (8.8) 65.8 (8.5) 64.7 (7.9) 
Glucose (mg/dl)a 91.3 (9.2) 91.0 (9.7) 91.6 (9.4) 91.4 (9.2) 91.0 (8.7) 90.1 (8.7) 
Total cholesterol 
(mg/dl)a 
187.4 (31.6) 188.5 (31.8) 188.4 (31.5) 187.3 (31.4) 185.2 (31.6) 183.8 (32.1) 
LDL-C (mg/dl)a 113.6 (29.4) 114.5 (29.7) 115.1 (29.6) 113.5 (29.2) 111.0 (28.8) 109.0 (28.6) 
HDL-C (mg/dl)a 63.0 (14.9) 63.2 (15.2) 62.3 (14.9) 63.1 (14.8) 63.9 (14.8) 64.8 (14.4) 
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Triglycerides (mg/dl)c 75 (57-103) 75 (56-104) 76 (58-105) 75 (57-103) 72 (56-98) 71 (54-95) 
ALT (U/l)c 15 (11-20) 15 (11-20) 15 (12-21) 15 (11-20) 13 (11-18) 12 (10-16) 
GGT (U/l)c 15 (11-22) 15 (11-23) 16 (12-24) 15 (11-22) 13 (10-19) 12 (10-17) 
HOMA-IRc 1.04 (0.71-1.48) 1.01 (0.68-1.44) 1.02 (0.69-1.46) 1.05 (0.71-1.49) 1.08 (0.73-1.53) 1.08 (0.73-1.53) 
hsCRP (mg/l)c 0.3 (0.2-0.6) 0.3 (0.2-0.7) 0.3 (0.2-0.7) 0.3 (0.2-0.6) 0.3 (0.2-0.6) 0.3 (0.2-0.6) 












Poor sleep quality (%) 20.1 45.8 21.8 13.2 10.8 13.4 
Data are expressed as the a mean (standard deviation), c median (interquartile range), or percentage. b ≥ 10 g of ethanol per day; d ≥ college 
graduate; e among 143,306 subjects with plausible estimated energy intake levels (within three standard deviations from the log-transformed 
mean energy intake)  
Abbreviations: CVD, cardiovascular disease; ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; HDL-C, high-density 
lipoprotein cholesterol; HEPA, health-enhancing physical activity; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model 












Table 2. Hazard ratios a (95% CI) of incident hepatic steatosis (regardless of fibrosis score) by sleep duration and subjective sleep quality 
 Sleep duration (hours) P for 
trend 
Subjective sleep quality 
≤5 6 7 8 ≥9 Good Poor 
Person-years (PY) 78,095 204,972 216,532 97,316 21,668  498,010 120,573 
Incident cases 4,128 10,567 9,326 3,244 552  22,982 4,835 
Incidence density (/103 PY) 52.9  51.6  43.1  33.3 25.5   46.1 40.1  
Multivariable-adjusted HR          
  Model 1 1.24 (1.19-1.28) 1.09 (1.06-1.12) 1.0 0.97 (0.94 -1.01) 0.94 (0.86-1.03) <0.001 1.0 1.07 (1.04-1.11) 
Model 2 1.19 (1.14-1.23) 1.07 (1.04-1.10) 1.0 0.98 (0.94 -1.02) 0.95 (0.87-1.03) 0.002 1.0 1.00 (0.97-1.04) 
Model 3 1.07 (1.03-1.11) 1.02 (0.99-1.05) 1.0 0.99 (0.96-1.04) 1.00 (0.91-1.09)  0.001 1.0 1.05 (1.02-1.09) 
Model 4 1.10 (1.05-1.14) 1.03 (1.00-1.06) 1.0 0.97 (0.93-1.01) 0.95 (0.87-1.04) <0.001 1.0 1.03 (1.00-1.07) 
Time dependent model 1 b 1.20 (1.15-1.25) 1.07 (1.04-1.10) 1.0 0.97 (0.93-1.01) 0.88 (0.80-0.97) <0.001 1.0 0.97 (0.94-1.01) 
Time dependent model 2 b 1.06 (1.02-1.10) 1.01 (0.99-1.04) 1.0 0.99 (0.95-1.03) 0.95 (0.86-1.04) 0.001 1.0 1.02 (0.99-1.06) 
Time dependent model 3 b 1.16 (1.06-1.15) 1.03 (1.001-1.06) 1.0 0.98 (0.94-1.02) 0.91 (0.83-1.001) <0.001 1.0 1.00 (0.96-1.03) 
a Estimated from parametric proportional hazard models. Multivariable model 1 was adjusted for age and sex; model 2: model 1 plus adjustment for center, year 
of screening exam, season, alcohol consumption, smoking, physical activity, total energy intake, marital status, season, education level, depression, history of 
diabetes, and history of hypertension; model 3: model 2 plus adjustment for BMI; model 4: model 2 plus adjustment for waist circumference. 
b Estimated from parametric proportional hazard models with sleep duration, smoking, alcohol consumption, physical activity, total energy intake, marital 
status, depression, history of diabetes, and history of hypertension as time-dependent categorical variables and baseline age, sex, center, year of screening 
exam, education level as time-fixed variables: Time dependent model 2; Time dependent model 1 plus adjustment for BMI as time-varying variable; Time 
dependent model 3; Time dependent model 1 plus adjustment for waist circumference as time-varying variable 




Table 3. Hazard ratios a (95% CI) of incident hepatic steatosis (HS) plus intermediate/high probability of advanced fibrosis by sleep duration and subjective 
sleep quality 
 Sleep duration (hours) P for 
trend 
Subjective sleep quality 
≤5 6 7 8 ≥9 Good Poor 
HS + 
Intermediate/high based on Fib4 
        
Person-years (PY) 87,425 229,519 237,443 103,907 22,692  550,419 130,567 
Incident cases 232 591 461 163 24  1242 229 
Incidence density (/103 PY) 2.7  2.6  1.9  1.6  1.1   2.3  1.8  
Multivariable-adjusted HR         
  Model 1 1.37 (1.17-1.61) 1.16 (1.03-1.31) 1.0 1.11 (0.93-1.33) 1.06 (0.70-1.60) 0.002 1.0 1.08 (0.94-1.25) 
Model 2 1.30 (1.11-1.54) 1.14 (1.01-1.29) 1.0 1.11 (0.93-1.33) 1.08 (0.71-1.63) 0.021 1.0 0.97 (0.84-1.13) 
Model 3 1.19 (1.01-1.40) 1.08 (0.95-1.22) 1.0 1.14 (0.96-1.37) 1.14 (0.75-1.72) 0.392 1.0 1.02 (0.88-1.19) 
Model 4 1.25 (1.05-1.49) 1.08 (0.94-1.24) 1.0 1.03 (0.84-1.27) 0.99 (0.62-1.57) 0.038 1.0 0.96 (0.81-1.13) 
Time dependent model 1 b 1.21 (1.03-1.43) 1.03 (0.91-1.17) 1.0 0.86 (0.71-1.05) 1.03 (0.67-1.56) 0.006 1.0 1.03 (0.89-1.19) 
Time dependent model 2 b 1.06 (0.91-1.25) 0.97 (0.86-1.10) 1.0 0.89 (0.73-1.08) 1.08 (0.71-1.64) 0.339 1.0 1.08 (0.93-1.25) 
Time dependent model 3 b 1.09 (0.92-1.28) 0.99 (0.87-1.12) 1.0 0.86 (0.70-1.05) 1.03 (0.68-1.56) 0.139 1.0 1.05 (0.90-1.22) 
HS + 
Intermediate/high based on NFS 
        
Person-years (PY) 87081 228,463 236,841 103,769 22,657  548,535 130,274 
Incident cases 339 339 716  215  39  1911 353 
Incidence density (/103 PY) 3.9  4.2  3.0  2.1 1.7   3.5  2.7 
Multivariable-adjusted HR         
  Model 1 1.30 (1.14-1.48) 1.22 (1.11-1.35) 1.0 0.93 (0.80-1.09) 1.10 (0.80-1.53) <0.001 1.0 1.07 (0.95-1.20) 
Model 2 1.26 (1.10-1.44) 1.21 (1.10-1.33) 1.0 0.93 (0.80-1.09) 1.11 (0.80-1.53) <0.001 1.0 1.01 (0.90-1.14) 
Model 4 1.15 (1.00-1.34) 1.13 (1.01-1.26) 1.0 0.89 (0.74-1.06) 1.15 (0.80-1.63) 0.005 1.0 1.01 (0.88-1.15) 
Time dependent model 1 b 1.20 (1.05-1.37) 1.16 (1.05-1.28) 1.0 0.86 (0.73-1.01) 0.95 (0.67-1.35)  <0.001 1.0 0.99 (0.87-1.12) 
Time dependent model 3 b 1.01 (0.88-1.16) 1.07 (0.97-1.18) 1.0 0.86 (0.73-1.01) 0.97 (0.69-1.38) 0.065 1.0 1.02 (0.90-1.16) 
a Estimated from parametric proportional hazard models. Multivariable model 1 was adjusted for age and sex; model 2: model 1 plus adjustment for center, year 
of screening exam, season, alcohol consumption, smoking, physical activity, total energy intake, marital status, season, education level, depression, history of 
diabetes (only for FIB4), and history of hypertension; model 3: model 2 plus adjustment for BMI; model 4: model 2 plus adjustment for waist circumference. 
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b Estimated from parametric proportional hazard models with sleep duration, smoking, alcohol consumption, physical activity, total energy intake, marital 
status, depression, history of diabetes, and history of hypertension as time-dependent categorical variables and baseline age, sex, center, year of screening 
exam, education level as time-fixed variables: Time dependent model 2; Time dependent model 1 plus adjustment for BMI as time-varying variable; Time 
dependent model 3; Time dependent model 1 plus adjustment for waist circumference as time-varying variable 
















Table 4. Hazard ratios a (95% CI) of incident hepatic steatosis (HS) without or with intermediate/high probability of advanced fibrosis by sleep duration 
among subjects with and without poor sleep quality 
 Sleep duration (hours) P for trend P for 
≤5 6 7 8 ≥9 interaction 
HS regardless of fibrosis score        
Sleep quality       0.743 
Good (N=114,577) 1.20 (1.15-1.25) 1.08 (1.04-1.11) 1.0 0.98 (0.94-1.03) 0.94 (0.86-1.03) <0.001  
Poor (N=28,729) 1.13 (1.05-1.23) 1.05 (0.97-1.13) 1.0 0.94 (0.83-1.08) 0.99 (0.78-1.26) <0.001  
HS+ Intermediate/high FIB-4        
Sleep quality       0.047 
Good (N=114,577) 1.31 (1.08-1.58) 1.11 (0.97-1.26) 1.0 1.12 (0.93-1.35) 0.85 (0.52-1.38) 0.033  
Poor (N=28,729) 1.45 (0.97-2.15) 1.41 (0.96-2.08) 1.0 0.95 (0.46-1.98) 3.33 (1.48-7.51) 0.365  
HS+ Intermediate/high NFS        
Sleep quality       0.068 
Good (N=114,577) 1.28 (1.10-1.49) 1.18 (1.07-1.31) 1.0 0.90 (0.77-1.06) 0.94 (0.65-1.36) <0.001  
Poor (N=28,729) 1.36 (0.99-1.88) 1.44 (1.06-1.97) 1.0 1.34 (0.80-2.23) 2.72 (1.34-5.51) 0.684  
a Estimated from parametric proportional hazard models. Multivariable model was adjusted for age, sex, center, year of screening exam, season, alcohol 
consumption, smoking, physical activity, total energy intake, marital status, season, education level, depression, history of diabetes (not for HS+ 
Intermediate/high NFS) , and history of hypertension 
P for quadratic term =0.001 for the association between sleep duration and incident HS; P for quadratic term =0.08 for the association between sleep duration 
and incident HS plus intermediate/high FIB-4; and P for quadratic term =0.192 for the association between sleep duration and incident HS plus intermediate/high 
NFS among participants with poor sleep quality 






Figure 1. Flowchart of the included subjects. 
 
 
Figure 2. Multivariable-adjusted HRs for NAFLD. The curves represent adjusted HRs for incident NAFLD based on restricted cubic splines with 
knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of sleep duration distribution. The model was adjusted for age, sex, center, year of the 
screening exam, BMI, alcohol consumption, smoking, physical activity, total energy intake, marital status, education level, depression, history of 

















S1. Measurement  
  Pittsburgh Sleep Quality Index (PSQI), 19-item self-administered questionnaire, at 
baseline and during the follow-up sessions was used to assess sleep duration and quatliy.(1) It 
consists of seven components, including subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime 
function. Each component score ranges from 0 (best) to 3 (worst sleep properties), and the 
PSQI score is calculated as the sum of each component score to generate an overall score. In 
one of the PSQI items, the subjects were asked to report the hours of actual asleep at night in 
a typical 24 h period over the previous month. Sleep duration was obtained by rounding 
values of 30 min or more up to the nearest hour and rounding values less than 30 min down to 
the nearest hour. Sleep quality was categorized into two groups (good: PSQI score <6, poor: 
PSQI score ≥6) (1). Sleep duration were grouped into ≤5, 6, 7, 8, and ≥9 h. Since 7 hours per 
day or more for adults are considered appropriate to maintain ideal health,(2) 7 hours was 
chosen as the reference and shorter duration was defined as short sleep duration.  
Depressive symptoms were assessed using the Korean version of the Center for 
Epidemiologic Studies Depression (CES-D) scale and were categorized as a CES-D score of 
<16 and ≥16.(3, 4)  
Physical activity levels were assessed using the validated Korean version of the International 
Physical Activity Questionnaire Short Form.(5, 6) Health-enhancing physical activity (HEPA) 
was defined as follows: (1) vigorous activity ≥3 days/week with ≥1,500 accumulated metabolic 
equivalent (MET)-minutes/week, or (2) a combination of walking, moderate- or vigorous-
intensity activities for 7 days accumulating to ≥3,000 MET-min/week. 
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Sitting blood pressure (BP), height, weight, and waist circumference were measured 
by trained nurses. Hypertension was defined as a systolic blood pressure ≥140 mmHg, diastolic 
blood pressure ≥90 mmHg, or current use of antihypertensive medication.  
 
Blood and urine specimens were collected after at least 10 h of fasting. Fasting blood 
sample measurements included total cholesterol, low density lipoprotein-cholesterol (LDL-C), 
high density lipoprotein-cholesterol (HDL-C), triglycerides, AST, ALT, gamma-glutamyl 
transferase (GGT), glucose, uric acid, hsCRP, albumin, and platelet count. The homeostatic 
model assessment of insulin resistance (HOMA-IR) index was calculated as follows: fasting 
blood insulin (mU/mL) × fasting blood glucose (mmol/L)/22.5. 
 
S2. Assessment of hepatic steatosis and non-invasive fibrosis score 
 The diagnosis of hepatic steatosis was determined using standard criteria, including 
the presence of a diffuse increase in fine echoes in the liver parenchyma compared with the 
kidney or spleen parenchyma, deep beam attenuation, and bright vessel walls.(7) Inter-
observer and intra-observer reliability values for HS diagnoses were moderate to substantial 
(kappa statistic of 0.74) (8, 9) and excellent (kappa statistic of 0.94), respectively.(10) 
The FIB-4 index was calculated using the following formula: FIB-4 = [age (years) × 
AST (U/L)] / [platelet count (×109/L) × ALT (U/L)1/2]. The subjects were classified into three 
groups, reflecting the probability of advanced fibrosis based on the FIB-4 score: low (FIB-4 
<1.30), intermediate (FIB-4 1.30-2.66), and high (FIB-4 ≥2.67).(11) NFS was calculated 
according to the following published formula: NFS = -1.675 + 0.037 × age (years) + 0.094 × 
BMI (kg/m2) + 1.13 × impaired fasting glycemia or diabetes (yes = 1, no = 0) + 0.99 × 
AST/ALT ratio - 0.013 × platelet (×109/L) - 0.66 × albumin (g/dL).(12) Subjects were also 
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categorized into three groups reflecting the probability of advanced fibrosis based on the 
NFS: high (NFS >0.676), intermediate (NFS: 0.676 to -1.455), and low (NFS < -1.455).(12) 
 
S3. Statistical modeling for data analysis 
The models were initially adjusted for age and sex and then adjusted for study center (Seoul, 
Suwon), year of the screening exam, season (spring, summer, fall, and winter), smoking (never, 
past, current, or unknown), alcohol intake (none, < 10, or ≥ 10 g/day, or unknown), physical 
activity (inactive, minimally active, health-enhancing physical activity (HEPA), or unknown), 
CES-D (<16, ≥ 16, or unknown), education level (< community college graduate, ≥ community 
college graduate, or unknown), total energy intake, history of diabetes, history of hypertension, 
and history of CVD (Model 2). Next, we sought to examine whether the relationship between 
sleep duration and development of the primary endpoints was mediated by body mass index 
(BMI) as a continuous variable (Model 3) on a priori grounds.   
We evaluated the mediation effect of BMI on the association between sleep duration and risk 
of HS or HS plus an intermediate/high probability of liver fibrosis (Model 4) if the BMI met 
the three criteria for being a potential mediator as follows: 1) sleep duration was associated 
with BMI, 2) BMI was significantly associated with the incident endpoint when sleep 
duration was included in the model, and 3) the addition of BMI to the model attenuated the 
association between sleep duration and incident HS. To explore the role of central obesity, 
these analyses were repeated when BMI was replaced by waist circumference (Model 4). 
To further explore the shape of the dose-response relationship of sleep duration with the 
development of NAFLD, restricted cubic splines with knots were used at the 5th, 27.5th, 50th, 
72.5th, and 95th percentiles of sleep duration. We then evaluated whether the associations 
between sleep duration and the risk of NAFLD differed by sleep quality. The interactions 
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between sleep quality and sleep duration categories on the risk of NAFLD were tested using 
likelihood ratio tests. These tests were used to compare the models with and without 
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